DJIA 16,399.67 19.26 0.12%
NASDAQ 4,316.07 57.64 1.35%
S&P 500 1,904.01 17.25 0.91%
market minute promo


company name or ticker

Bank Of America Q3 Small & Mid-Cap Biotech Preview

Orexigen Launches Contrave - Watch For Traction

Belviq Sales Dip: What To Watch For Ahead

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

What To Watch For As Orexigen's Launch Approaches

Pfizer Setback Could Help Arena

Belviq Sales Rise Almost 5% Week Over Week

Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BE

Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ (lorcaserin HCl) CIV In Postgraduate Medicine

3 Biotech Stocks Near 52-Week Lows Worth Buying

These may be cheap biotech stocks, but they may not be cheap for long according to the three analysts we asked.

The 1 Biotech Stock I'm Definitely Not Buying

Three of our analysts chime in on which biotech stocks they think are the most risky.
See More Articles...